Clinical Trials Logo
  1. Home
  2. Aspirin
  3. NCT03424408

Serum Thromboxane B2 Assay as a Measure of Platelet Production in Healthy Volunteers Taking Aspirin

Aspirin Clinical Trial

Official title:
Serum Thromboxane B2 Assay as a Measure of Platelet Production in Healthy Volunteers Taking Aspirin

Clinical Trial Summary

Some aspirin-treated patients have a blunted pharmacological response predisposing to clinical failure. The investigators hypothesize that the blunted response often results from increased rate of platelet production and some failures will be prevented by administering aspirin twice daily. The overall objective is to develop a valid method to quantify platelet production (without the use of radioactive isotopes) in order to examine the hypothesis that enhanced platelet production is a common cause of poor aspirin responsiveness in patients with atherothrombosis.

Clinical Trial Description

The specific objective of this study is to validate the Cayman Chemical serum thromboxane immunoassay as a measure of platelet production in healthy subjects who are treated with aspirin by demonstrating that the recovery of their serum thromboxane B2 levels occurs at a rate of about 10% per day after aspirin cessation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03424408
Study type Interventional
Source Hamilton Health Sciences Corporation
Contact
Status Completed
Phase N/A
Start date March 1, 2018
Completion date September 3, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT00978159 - Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Phase 4
Completed NCT04153760 - Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity Early Phase 1
Recruiting NCT03356769 - Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Phase 2
Recruiting NCT06185621 - The Effect of Aspirin on Recurrent Acute Pancreatitis N/A
Completed NCT05278637 - GM03 - Platelet RNA Signatures of Aspirin Early Phase 1
Completed NCT01582217 - Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition N/A
Recruiting NCT01268917 - The Effects of Preoperative Aspirin on Graft Patency and Cardiac Events in Off-pump Coronary Artery Bypass Phase 3
Recruiting NCT03450317 - Influence of Aspirin on Human Gut Microbiota Composition and Metabolome N/A
Completed NCT03871517 - INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE Phase 4
Recruiting NCT05802940 - Low Dose Aspirin Alerts in High-Risk Pregnancies N/A
Recruiting NCT05702463 - Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II Phase 1
Completed NCT01900639 - Aspirin AM or PM: Effect on Circadian Rhythm of Platelet Reactivity Phase 4
Recruiting NCT03188471 - Preventive Application of GnRH Antagonist on Early OHSS Phase 4
Recruiting NCT03005704 - Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets N/A
Recruiting NCT03785015 - When Should Low-dose Aspirin be Resumed After Peptic Ulcer Bleeding? N/A
Completed NCT00753753 - VerifyNow French Registry N/A
Recruiting NCT04356326 - Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy Phase 3
Recruiting NCT04214990 - Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients Phase 3
Enrolling by invitation NCT04365309 - Protective Effect of Aspirin on COVID-19 Patients Phase 2/Phase 3
Completed NCT05512546 - The Prevention of Thromboembolic Complications Associated With Coil Embolization